- Home
- CRBP vs NVNO Comparison
CRBP vs NVNO Comparison
Compare CRBP & NVNO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- NVNO
- Stock Information
- Founded
- CRBP 2009
- NVNO 1987
- Country
- CRBP United States
- NVNO United States
- Employees
- CRBP N/A
- NVNO N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- NVNO Medical/Dental Instruments
- Sector
- CRBP Health Care
- NVNO Health Care
- Exchange
- CRBP Nasdaq
- NVNO Nasdaq
- Market Cap
- CRBP 73.4M
- NVNO 78.7M
- IPO Year
- CRBP N/A
- NVNO N/A
- Fundamental
- Price
- CRBP $8.33
- NVNO $4.05
- Analyst Decision
- CRBP Strong Buy
- NVNO
- Analyst Count
- CRBP 10
- NVNO 0
- Target Price
- CRBP $53.56
- NVNO N/A
- AVG Volume (30 Days)
- CRBP 123.5K
- NVNO 135.7K
- Earning Date
- CRBP 08-05-2025
- NVNO 07-30-2025
- Dividend Yield
- CRBP N/A
- NVNO N/A
- EPS Growth
- CRBP N/A
- NVNO N/A
- EPS
- CRBP N/A
- NVNO N/A
- Revenue
- CRBP N/A
- NVNO N/A
- Revenue This Year
- CRBP N/A
- NVNO N/A
- Revenue Next Year
- CRBP $150.03
- NVNO $409.09
- P/E Ratio
- CRBP N/A
- NVNO N/A
- Revenue Growth
- CRBP N/A
- NVNO N/A
- 52 Week Low
- CRBP $4.64
- NVNO $2.03
- 52 Week High
- CRBP $61.90
- NVNO $6.48
- Technical
- Relative Strength Index (RSI)
- CRBP 54.09
- NVNO 54.46
- Support Level
- CRBP $8.10
- NVNO $4.19
- Resistance Level
- CRBP $9.45
- NVNO $4.52
- Average True Range (ATR)
- CRBP 0.52
- NVNO 0.39
- MACD
- CRBP -0.08
- NVNO -0.01
- Stochastic Oscillator
- CRBP 55.74
- NVNO 47.29
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About NVNO enVVeno Medical Corporation
enVVeno Medical Corp is a late clinical-stage medical device company focused on advancing bioprosthetic (tissue-based) solutions to improve the standard of care for treating venous disease. The company's product, VenoValve, is a surgical replacement venous valve that is currently being evaluated in a U.S. pivotal study. The company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the products are designed to act as one-way valves to help assist in propelling blood up the veins of the leg, and back to the heart and lungs. The company has determined that it currently operates in a single segment, Medical Device development, located in a single geographic location, the United States.